A Preliminary Study of the Complement Component 1q Levels in Predicting the Efficacy of Combined Immunotherapy in Patients with Lung Cancer

References

• AroraS, VelichinskiiR, LeshRW, et al. Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumors. Adv Ther. 2019;36:4. doi:10.1007/s12325-019-01051-z
   Web of Science ®Google Scholar
• MinYT, SeierK, OstrovnayaI, et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers. J Clin Oncol. 2018;36(17):1685–1694. doi:10.1200/JCO.2017.75.774029489427
   PubMed Web of Science ®Google Scholar
• IchikiY, TairaA, ChikaishiY, et al. Prognostic factors of advanced or postoperative recurrent non-small cell lung cancer targeted with immune check point inhibitors. J Thorac Dis. 2019;11(4):1117–1123. doi:10.21037/jtd.2019.04.4131179053
   PubMed Web of Science ®Google Scholar
• CorralesL, AjonaD, RafailS, et al. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol. 2012;189(9):4674. doi:10.4049/jimmunol.120165423028051
   PubMed Web of Science ®Google Scholar
• WolchokJD, HoosA, O’DayS, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–7420. doi:10.1158/1078-0432.CCR-09-162419934295
   PubMed Web of Science ®Google Scholar
• TartaroneA, RovielloG, LeroseR, et al. Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis. Future Oncol. 2019;15(20):2423–2433. doi:10.2217/fon-2018-086831237152
   PubMed Web of Science ®Google Scholar
• SobhaniN, Tardiel-CyrilDR, DavtyanA, et al. CTLA-4 in regulatory T cells for cancer immunotherapy. Cancers. 2021;13(6):1440. doi:10.3390/cancers1306144033809974
   PubMed Web of Science ®Google Scholar
• ZhuJ, LiR, TiseliusE, et al. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. Cochrane Database Syst Rev. 2017;12(12):CD011300. doi:10.1002/14651858.CD011300.pub229247502
   PubMed Web of Science ®Google Scholar
• MohsenzadeganM, PengRW, RoudiR, et al. Dendritic cell/cytokine-induced killer cell-based immunotherapy in lung cancer: what we know and future landscape. J Cell Physiol. 2020;235(1):74–86. doi:10.1002/jcp.2897731222740
   PubMed Web of Science ®Google Scholar
• PetrelliF, FerraraR, SignorelliD, et al. Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis. Immunotherapy. 2021;13(7):621–631. doi:10.2217/imt-2020-022433775103
   PubMed Web of Science ®Google Scholar
• FathiZ, MousaviSAJ, RoudiR, et al. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: an analysis of Iranian patients. PLoS One. 2018;13(7):e0200633. doi:10.1371/journal.pone.020063330048458
   PubMed Web of Science ®Google Scholar
• SunX, RoudiR, DaiT, et al. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. BMC Cancer. 2019;19(1):558. doi:10.1186/s12885-019-5701-631182061
   PubMed Web of Science ®Google Scholar
• MotzerRJ, EscudierB, McdermottDF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813. doi:10.1056/NEJMoa151066526406148
   PubMed Web of Science ®Google Scholar
• CarboneDP, ReckM, Paz-AresL, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376(25):2415–2426. doi:10.1056/NEJMoa161349328636851
   PubMed Web of Science ®Google Scholar
• Georg.H. PD-L1 testing, fit for routine evaluation? From a pathologist’s point of view. Memo. 2016;9(4):201–206. doi:10.1007/s12254-016-0292-228058063
   PubMedGoogle Scholar
• WangSY, WeinerG. Complement and cellular cytotoxicity in antibody therapy of cancer. Expert Opin Biol Ther. 2008;8(6):759–768. doi:10.1517/14712598.8.6.75918476787
   PubMed Web of Science ®Google Scholar
• ReisES, MastellosDC, RicklinD, et al. Complement in cancer: untangling an intricate relationship. Nat Rev Immunol. 2018;18(1):5–18. doi:10.1038/nri.2017.9728920587
   PubMed Web of Science ®Google Scholar
• ChoMS, VasquezHG, RupaimooleR, et al. Autocrine effects of tumor-derived complement. Cell Rep. 2014;6(6):1085–1095. doi:10.1016/j.celrep.2014.02.01424613353
   PubMed Web of Science ®Google Scholar
• LuJ, KishoreU. C1 complex: an adaptable proteolytic module for complement and non-complement functions. Front Immunol. 2017;8:592. doi:10.3389/fimmu.2017.0059228596769
   PubMed Web of Science ®Google Scholar
• ReidKKBM. C1q: structure, function, and receptors. Immunopharmacology. 2000;49(1–2):159–170. doi:10.1016/s0162-3109(00)80301-x10904115
   PubMed Web of Science ®Google Scholar
• BullaR, TripodoC, RamiD, et al. C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. Nat Commun. 2016;7(1):10346. doi:10.1038/ncomms1034626831747
   PubMed Web of Science ®Google Scholar
• AgostinisC, VidergarR, BelmonteB, et al. Complement protein C1q binds to hyaluronic acid in the malignant pleural mesothelioma microenvironment and promotes tumor growth. Front Immunol. 2017;8:1559. doi:10.3389/fimmu.2017.0155929209316
   PubMed Web of Science ®Google Scholar
• HongQ, SzeCI, LinSR, et al. Complement C1q activates tumor suppressor WWOX to induce apoptosis in prostate cancer cells. PLoS One. 2009;4(6):e5755. doi:10.1371/journal.pone.000575519484134
   PubMed Web of Science ®Google Scholar
• RoumeninaLT, DauganMV, NoéR, et al. Tumor cells hijack macrophage-produced complement C1q to promote tumor growth. Cancer Immunol Res. 2019;7(7):1091–1105. doi:10.1158/2326-6066.CIR-18-089131164356
   PubMed Web of Science ®Google Scholar
• HerbstRS, BaasP, KimDW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015;387(10027):1540–1550. doi:10.1016/S0140-6736(15)01281-726712084
   PubMed Web of Science ®Google Scholar
• BorghaeiH, Paz-AresL, HornL, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015:123–135. doi:10.1056/NEJMoa150764326028407
   PubMed Web of Science ®Google Scholar
• BrahmerJ, ReckampKL, BaasP, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135. doi:10.1056/NEJMoa150462726028407
   PubMed Web of Science ®Google Scholar
• KoukourakisMI, GiatromanolakiA, SivridisE, et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer. 2003;89(5):877–885. doi:10.1038/sj.bjc.660120512942121
   PubMed Web of Science ®Google Scholar
• MezquitaL, AuclinE, FerraraR, et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non–small cell lung cancer. JAMA Oncol. 2018;4(3):351–357. doi:10.1001/jamaoncol.2017.477129327044
   PubMed Web of Science ®Google Scholar
• TaniguchiY, TamiyaA, IsaSI, et al. Predictive factors for poor progression-free survival in patients with non-small cell lung cancer treated with nivolumab. Anticancer Res. 2017;37(10):5857–5862. doi:10.21873/anticanres.1203028982912
   PubMed Web of Science ®Google Scholar